Agios Pharmaceuticals | AGIO - 销售和管理费用



金融业
股票价格
USD
资产
USD 1.18B
现金及等价物
USD 113.6M
销售成本
USD 1.32M
流动资产
USD 834.84M
流动负债
USD 58.85M
债务
USD 40.21M
EBIT
USD -110.03M
EBITDA
USD -120.31M
员工
486
EPS每股收益
USD -1.69
股本和储备
USD 1.11B
销售毛利
USD 19.43M
债务利息支出
USD 1.18B
利息收入
USD 12.41M
贷款资金
USD 1.06M
市值
USD 2.2B
净收入
USD -99.11M
营业费用
USD 130.77M
营业利润
USD -110.03M
普通股股本
USD 59.34M
PE价格收益
3.56
税前利润
USD -99.11M
销售收入
USD 18.8M
销售和管理费用
USD 38.46M
股票
USD 35.09M
贸易债权人
USD 13.75M
应收帐款人
USD 16.13M


销售和管理费用 更改 日
AbbVie USD 3.58B 316M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Arrowhead Research USD 41.74M 4.28M 2026-03
Astellas Pharma JPY 234.7B 12.92B 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bayer EUR 3.7B 356M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Exelixis USD 139.6M 16.58M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.14B 296M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03